Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 3;11(3):20458940211032125.
doi: 10.1177/20458940211032125. eCollection 2021 Jul-Sep.

Bufei huoxue capsules in the management of convalescent COVID-19 infection: study protocol for a multicenter, double-blind, and randomized controlled trial

Yuqin Chen  1 , Wenjun He  1 , Wenju Lu  1 , Yue Xing  1 , Jianling Bai  2 , Hao Yu  2 , Jiawei Zhou  2 , Jingyi Liang  1 , Jiyuan Chen  1 , Chi Hou  1   3 , Bihua Zhong  1 , Ting Wang  4 , Huazhuo Feng  1 , Xu Chen  1 , Tao Wang  1 , Kai Yang  1 , Nuofu Zhang  1 , Nanshan Zhong  1 , Chunli Liu  1 , Jian Wang  1
Affiliations

Bufei huoxue capsules in the management of convalescent COVID-19 infection: study protocol for a multicenter, double-blind, and randomized controlled trial

Yuqin Chen et al. Pulm Circ. .

Abstract

Up to 30 May 2021, the cumulative number of patients diagnosed with corona virus disease-19 (COVID-19) globally has exceeded 170 million, with more than 152 million patients recovered from COVID-19. However, the long-term effect of the virus infection on the human body's function is unknown for convalescent patients. It was reported that about 63% of COVID-19 patients had observable lung damage on CT scans after being released from the hospital. Bufei Huoxue (BFHX) capsules, including three active ingredients of traditional Chinese herbal medicine, has been used clinically to prevent and treat pulmonary heart diseases with Qi deficiency and blood stasis syndrome. Some small-scale clinical trials have found that BFHX can improve lung ventilation function, reduce blood viscosity, and improve cardiopulmonary function. However, the efficacy and safety of BFHX in the treatment of the recovery phase of COVID-19 are unknown. This study is a multicenter, double-blinded, randomized, controlled trial. Subjects with convalescent COVID-19 were randomized (1:1) into either a BFHX or control group and observed for three months concomitant with receiving routine treatment. The primary efficacy indicators are the evaluation results and changes of the St. George's Respiratory Questionnaire score, Fatigue Assessment Inventory, and 6-min walk distance. Based on the intention-to-treat principle, all randomly assigned participants will be included in the statistical analysis. The last visit's outcomes will be used as the final outcomes for participants who prematurely withdraw from the trial. Per protocol set will pick up from the full analysis set for analysis. Efficacy analysis will be performed on the intention-to-treat datasets and per-protocol datasets. This study and its protocol were approved by the Ethics Committee of our University. Prior to participation, all subjects provided written informed consent. Results will be disseminated at medical conferences and in journal publications. We aimed to determine the efficacy and safety of BFHX for the treatment of the convalescent COVID-19 patients. Trial registration number: ChiCTR2000032573.

Keywords: Bufei Huoxue capsules; novel coronavirus 2019; randomized controlled trial; recovery period.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Jian Wang has received a research grant from Guangdong Leiyunshang Pharmaceutical Co., Ltd.

References

    1. Worldometer. COVID-19 coronavirus pandemic, https://www.worldometers.info/coronavirus/ (2021, accessed 30 May 2021).
    1. Shaw B, Daskareh M, Gholamrezanezhad A. The lingering manifestations of COVID-19 during and after convalescence: update on long-term pulmonary consequences of coronavirus disease 2019 (COVID-19). Radiol Med. Epub ahead of print 1 October 2020. DOI: 10.1007/s11547-020-01295-8 - PMC - PubMed
    1. Sonnweber T, Sahanic S, Pizzini A, et al.. Cardiopulmonary recovery after COVID-19 – an observational prospective multi-center trial. Eur Respir J. Print 2021 Apr. DOI: 10.1183/13993003.03481-2020 - PMC - PubMed
    1. Lei Yun Shang Pharmaceutical Group Co., Ltd. The official production introduction of Bufei Huoxue Capsules, http://www.lys.cn/productsandintroductions/info.aspx?itemid=55&Lcid=20 (2021, accessed 30 May 2021).
    1. Li Y, Dongqing Y. Improving the body's immunity and delaying aging – on the new medicinal uses of Ginkgo biloba, berries, and astragalus. Chin J Pract Tradit Chin West Med 2003; 016: 1649.

LinkOut - more resources